Aldeyra Therapeutics, Inc. ALDX was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 90.1% in the past one-month time frame.
The move came after the company announced impressive results from a phase IIb study evaluating its topical ocular Reproxalap as a treatment for dry eye disease.
The company has seen one negative estimate revision in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Aldeyra Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Aldeyra Therapeutics, Inc. Price
Aldeyra Therapeutics, Inc. Price | Aldeyra Therapeutics, Inc. Quote
A better-ranked stock in the Medical – Drugs industry is BioSpecifics Technologies Corp BSTC, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ALDX going up? Or down? Predict to see what others think: Up or Down
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment